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ABSTRACT  
 
Background: We investigated the prevalence of, and evaluated screening modalities 
for, undiagnosed tuberculosis in ART-eligible adults in South Africa.  
 
Methods: Individuals were screened for tuberculosis using symptoms, chest 
radiograph and two sputum specimens for microscopy and culture, then followed for 
<6 months to determine tuberculosis diagnoses.   
 
Results: Among 361 participants (67% female, median age 38, median CD4 count 
120 cells/mm3), 64/361 (18%) participants were sputum culture positive. 114 (32%) 
fulfilled any tuberculosis case definition (culture and/or smear positive; or 
improvement on specific treatment). A symptom screen comprising any of: cough or 
appetite loss or night sweats >2 weeks had sensitivity and specificity of 74.5% and 
50.8% respectively. Sensitivity was increased by chest radiography (to 96.1%) but 
not by sputum microscopy. The WHO symptom screen had sensitivity and specificity 
of 96.1% and 5.2% respectively in our study population; addition of chest radiography 
increased sensitivity to 100%. Median time to TB treatment was 8 days for diagnoses 
based on chest radiograph (N=72), vs. 37 days for diagnoses based only on sputum 
culture (N=14).  
 
Conclusions: The very high prevalence of undiagnosed tuberculosis among patients 
presenting for ART mandates their routine investigation.  Chest radiography 
improved sensitivity substantially, allowed rapid treatment initiation and should be 
routine, where available, pending better point-of-care diagnostics. 
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INTRODUCTION   
Tuberculosis remains a key cause of death among people with HIV1 in sub-Saharan 
Africa despite wider use of antiretroviral therapy (ART).2-4 Diagnosis is complicated 
by the high proportion who are smear-negative,5,6 and atypical chest radiograph 
findings.7   
 
Intensified tuberculosis case finding (ICF) is recommended by the World Health 
Organization (WHO)8 but is poorly implemented.9 Screening prior to ART is 
particularly important because risk of tuberculosis and death is high for 
immunosuppressed individuals.4,10 Individuals diagnosed with tuberculosis after, 
rather than before, ART initiation are more likely to die while on tuberculosis 
treatment, emphasising the need for prompt diagnosis and treatment initiation.3 High 
tuberculosis incidence within the first few months of ART initiation suggests that 
cases are either missed at screening or subclinical disease is unmasked by 
immunological recovery.10-12  
 
The aim of our study was to determine the prevalence of previously undiagnosed 
active tuberculosis amongst ART-eligible adults at enrolment to a public sector HIV 
clinic in South Africa, and to evaluate the performance of combinations of symptoms 
and standard investigations in the diagnosis of tuberculosis.  
 
 
METHODS  
Study design and population 
Between August 2007 and January 2008, we recruited ART-eligible (WHO stage 4 or 
CD4<200 cells/mm3)13 adults (>17 years) to a prospective cohort study.  Patients 
taking tuberculosis treatment currently or within the previous three months were 
excluded.   
 
Patients were referred to this clinic for ART initiation. South African guidelines13 at 
the time of this study did not specify systematic screening for tuberculosis prior to 
ART. Clinic policy was for routine chest radiography at enrolment, but systematic 
tuberculosis screening was not routine; patients were assessed by clinicians for ART 
eligibility and investigated as deemed appropriate. All patients with CD4<200 
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cells/mm3, or CD4<350 cells/mm3 and WHO stage 2, 3 or 4 received cotrimoxazole; 
isoniazid preventive therapy was not given. Patients on tuberculosis treatment 
started ART after two weeks if CD4 count<50 cells/mm3 or other serious HIV-related 
illness, or two months if CD4 count between 50 and 200 cells/mm3 or WHO stage 4.   
 
 
Study procedures 
Trained nurses administered a symptom questionnaire and collected two spot 
sputum specimens for smear and mycobacterial culture from all participants. Chest 
radiographs were read by a consultant physician blinded to clinical details, using a 
standardised form adapted from a validated tool,14 assigning radiographic diagnoses 
according to overall impression. We reviewed patients 3-6 months post enrolment, 
performing repeat symptom questionnaire and record review, and investigated 
symptomatic patients with chest radiography and two further sputum specimens. 
Symptomatic patients were those with any of: cough, night sweats, fever, appetite 
loss, tiredness for >2 weeks; or haemoptysis, chest pain, difficulty breathing, 
observed weight loss >1.5kg in previous month; or self-reported weight loss over the 
preceding 6 months. Patient records were used to ascertain CD4 and full blood 
counts, WHO clinical stage, tuberculosis diagnoses made outside of study visits, and 
evidence of clinical improvement at two months amongst those on tuberculosis 
treatment. Tuberculosis diagnosed at recruitment was not used to assign WHO 
stage.  
  
 
Laboratory methods 
Sputum specimens were examined at the National Health Laboratory Services by 
fluorochrome staining for acid-fast bacilli (AFB), and cultured using the BACTECTM 
MGIT 960TM system (Becton Dickinson Microbiology Systems, Sparks, MD, USA). 
Scanty positive smears were considered positive. All positive cultures were identified 
using a nucleic amplification technique (AccuProbe®, Gen-Probe, San Diego, CA, 
USA).  
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Case definition for tuberculosis 
Patients were classified as having pulmonary tuberculosis (PTB) if they had 
compatible clinical or radiological features and: sputum culture-positive for M. 
tuberculosis (definite PTB); sputum smear-positive, culture-negative (probable PTB); 
or no other cause of disease found and clinical improvement after two months of 
tuberculosis treatment, or lost to follow-up or died before two months (possible PTB).  
 
Patients were classified as having extrapulmonary tuberculosis (EPTB) if they had 
compatible clinical features and either had: M. tuberculosis cultured from a relevant 
site (definite EPTB); other diagnostic evidence of EPTB and improved after two 
months of tuberculosis treatment (probable EPTB); or no other cause of disease was 
found and the patient improved after two months of tuberculosis treatment or was lost 
to follow-up or died before two months (possible EPTB). Tuberculosis episodes were 
considered to start on the date tuberculosis treatment was started.   
 
Prevalent tuberculosis was defined as any tuberculosis episode fulfilling case 
definitions within three months of enrolment. Only study screening tests performed 
on the day of enrolment were used to calculate sensitivity, specificity, negative and 
positive predictive values for screening methods. Information from all available 
sources was used to assign tuberculosis case definitions.  
 
 
Statistical analysis 
Data were analysed using Intercooled Stata 10.0 (Stata Corporation, Texas, USA). 
We used logistic regression to calculate unadjusted and adjusted odds ratios for risk 
factors for prevalent tuberculosis and to assess the performance of symptoms for a 
screening tool using a gold standard of culture-positive tuberculosis. Risk factor 
analyses were restricted to "definite" (culture-positive) cases, as a robust case 
definition, comparable with other studies,15,16 and probable and possible cases were 
excluded from these analyses.  A priori, the multivariable model for the risk factor 
analysis included CD4 count and age category as established risk factors for 
tuberculosis, and other factors for which the P value in the univariable analysis was 
≤0.2. From the multivariable model, we chose as screening criteria the three 
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symptoms with the highest adjusted odds ratios. We also evaluated the new WHO 
ICF screening tool of any of current cough, fever, weight loss or night sweats.17   
  
To estimate mortality rates pre-ART, person-time was calculated from date of 
recruitment to the study until the earliest of death; ART initiation; two weeks after last 
visit date (as all patients attend monthly to collect medication), or end of study (1st 
July 2008). For mortality after ART start, person-time was calculated from date of 
ART initiation until the earliest of death; two weeks after last visit date, or end of 
study.   
 
 
Ethical approval 
The study received ethical approval from the Research Ethics Committee of the 
University of KwaZulu-Natal and the London School of Hygiene & Tropical Medicine. 
Written informed consent, or witnessed verbal consent for participants unable to read 
or write, was obtained for all participants. 
 
 
RESULTS   
Participation and demographics 
Figure 1 summarises study inclusions and exclusions, losses to follow-up, and 
tuberculosis case definitions. Among 381 participants recruited, 12 were treated for 
tuberculosis without fulfilling our case definitions, and a further 8 were culture-
positive for non-tuberculous mycobacteria only. Amongst 361 participants analysed,  
99% were Black African, 67% were female, median age was 38 (IQR 32-46) years, 
median CD4 was 120 (IQR 72-168) cells/mm3 and 171/305 (56%) were WHO stage 3 
or 4. 100 (28%) reported a previous episode of tuberculosis, of whom 51% were 
treated ≤3 years ago.  
 
 
Prevalence of tuberculosis and basis of diagnosis  
114/361 participants fulfilled our case definition for tuberculosis (definite, probable or 
possible) giving a prevalence of undiagnosed tuberculosis of 32% (95% confidence 
interval [CI] 26.8-36.6%). "Possible" cases, vs. "definite", were more likely to have 
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more advanced WHO stage and EPTB only, but other markers of disease severity 
and radiographic patterns did not differ (see supplementary appendix table 1). 99/114 
(87%) had PTB, 5 (4%) had EPTB, and 10 (9%) had both. Overall 64 (56%), 6 (5%), 
and 44 (39%) were classified as definite, probable and possible tuberculosis 
respectively. The prevalence of culture-proven tuberculosis was 17.7% (64/361; 95% 
CI 13.9-22.1%). Amongst 360 patients with complete data, 110/113 (97%) of 
tuberculosis patients and 236/247 (96%) of patients without tuberculosis had at least 
one of the following symptoms: cough, fever, drenching night sweats, self-reported 
weight loss, haemoptysis, dyspnoea, chest pain, loss of appetite or fatigue. Amongst 
99 pulmonary tuberculosis cases (definite, probable and possible combined) the 
bases for diagnosis were: clinical, radiological, and microbiological (culture and/or 
smear) features for 39%; clinical and radiological features for 37%; clinical and 
microbiological features for 17%; and radiological and microbiological features for 
2%.   
 
 
Sputum microscopy and culture results 
Amongst 350 individuals with sputum results available, 24 (7%) and 326 (90%) 
produced one or two adequate sputum specimens respectively.  9/350 (3%) were 
smear-positive and 64/350 (18%) were culture-positive for M. tuberculosis, of whom 
one was culture-negative at enrolment but culture-positive subsequently. 7/350 (2%) 
were both smear- and culture-positive.  Amongst 300 patients with a negative or 
inadequate first sputum specimen, 14 (5%) had a culture-positive second specimen. 
57/64 (89%) of culture-positive patients were smear-negative. 
 
 
Time from screening to start of treatment 
Amongst 86 patients with definite, probable or possible tuberculosis, and for whom 
the basis of starting treatment was clear, the median time to starting treatment was 
13 (IQR 1, 35) days. 72/86 (84%) initiated treatment based on chest radiograph 
findings at median 8 (IQR 0, 24) days; of these 31/72 (43%) were initiated on the 
same or next day by the clinic doctor, and the remainder started treatment at a 
median of 20 (IQR 11, 36) days after enrolment, following further review of chest 
radiograph by consultant physician. 14/86 (16%) patients started treatment based on 
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sputum culture result at a median of 37 (IQR 20, 49) days and two (2%) patients 
started treatment based on sputum smear result after median 9 (IQR 4, 13) days post 
enrolment. Amongst 45 culture-confirmed tuberculosis cases, 29/45 (64%) started 
treatment based on chest radiograph findings at median 1 (IQR 0, 8) day vs. 35 (IQR 
20, 44) days for 14/45 (31%) patients started based on sputum culture result.     
 
Eight individuals had no evidence of active tuberculosis at the time of screening (and 
were included in the analysis as such) but at the time of final review were observed 
to have started tuberculosis treatment more than three months after screening 
(Figure 1). 
 
 
Demographic and clinical risk factors for undiagnosed prevalent tuberculosis 
Risk factor analyses were restricted to 300 individuals (6 “probable” and 44 “possible” 
tuberculosis cases, and 11 individuals without sputum results were excluded). In the 
univariable analysis (see supplementary appendix table 2), prevalent tuberculosis was 
associated with male sex, greater than six household members, ever having smoked, 
and no previous history of tuberculosis treatment. In the multivariable analysis only 
previous tuberculosis treatment, which was protective, (adjusted OR 0.29, 95% CI 
0.13-0.65) remained associated.  
  
 
Sensitivity, specificity and predictive values of markers for undiagnosed prevalent 
tuberculosis 
Using culture-positive tuberculosis as our gold standard we found that the presence 
of individual symptoms irrespective of duration was sensitive, but generally had low 
specificity, except for haemoptysis which had low prevalence (table 1). Addition of 
duration >2 weeks to individual symptoms reduced sensitivity, but improved 
specificity. Haemoglobin <10g/dl had a similar sensitivity to CD4 count<100 
cells/mm3 (38% vs. 35%), but had better specificity (80% vs. 62%). Sputum 
microscopy was very insensitive particularly when compared to chest radiographic 
features of active tuberculosis (11% vs. 77%), and overall only 7/300 (2%) patients 
were smear positive. In a sensitivity analysis including all tuberculosis cases (definite, 
probable and possible), there was little change in sensitivity and specificity values 
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(data not shown) compared to those for only culture-positive tuberculosis cases. For 
example, sensitivity of radiographic features of active tuberculosis was 77.4% vs. 
80.4% for culture-positive vs. all tuberculosis cases.   
 
The symptom, sign, and investigation with best performance in terms of sensitivity 
and negative predictive value were, respectively: self-reported weight loss, BMI 
<18.5kg/m2, and any abnormality on chest radiograph (table 1). In terms of specificity 
and positive predictive value the best symptom, sign and investigation were fever >2 
weeks, observed fever (although only two participants were febrile), and sputum 
microscopy respectively.   
 
 
Combinations of screening criteria  
The three symptoms with the highest adjusted odds ratios in multivariable analysis 
were cough>2 weeks, loss of appetite >2 weeks and night sweats >2 weeks (for 
details, see supplementary appendix table 3). Amongst 244 individuals with complete 
data the performance of these in combination was tested (table 2). A combination of 
any of: cough or appetite loss or night sweats for greater than two weeks (henceforth 
known as the symptom complex) had sensitivity, specificity, positive and negative 
predictive values of 75%, 51%, 29% and 88% respectively. Adding BMI <18.5kg/m2 
to our symptom complex made little difference to sensitivity and negative predictive 
values, in contrast to WHO clinical stage 3 or 4 which increased sensitivity and 
negative predictive values to 90% but halved specificity. Addition of  haemoglobin 
<10g/dl improved the sensitivity and negative predictive value of the symptom 
complex to 82% and 90% respectively, and combining this with WHO stage 3 or 4 
and BMI <18.5 further increased sensitivity to 90% but halved specificity. 
 
Sputum microscopy did not change the performance of the symptom complex, in 
contrast to chest radiography which increased sensitivity to 92% for features 
compatible with active tuberculosis, and 96% for any radiographic abnormality. A 
combination of symptom complex or any radiographic abnormality had sensitivity and 
negative predictive values of 96%, which was further improved by addition of 
CD4<100 which missed only 2% of tuberculosis cases and was our most sensitive 
combination (98%).  
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The WHO symptom screen17 had sensitivity, specificity, positive and negative 
predictive values of 96%, 5%, 21% and 83% respectively in our patients. Addition of 
chest radiography increased sensitivity and negative predictive value to 100% for 
both features compatible with active tuberculosis and any radiographic abnormality. 
 
  
Time to ART start and mortality 
266/361 (74%) patients initiated ART by 1st July 2008, at median of 70 days from 
recruitment (IQR 42, 105). Among 266 patients who started ART within the study 
period, the median time from enrolment to ART start was shorter for those without 
tuberculosis (median 64 days, N=190) vs. those with tuberculosis (median 94 days, 
N=76). In total 26/361 patients (7.2%) died, of whom 20/26 (77%) did not initiate 
ART. The pre-ART mortality rate was 25.3/100 person-years (95% CI 16.3-39.1, vs. 
6.8/100 person-years (95% CI 3.0-15.1) after starting ART.  
 
Documented causes of death pre-ART (N=20) were tuberculosis (4); acute renal 
failure (2); 1 each of septicaemia, gastroenteritis, cryptococcal meningitis, 
cardiomyopathy, and pneumonia; and unknown (9; of whom three fulfilled case 
definitions for tuberculosis but did not start tuberculosis treatment). Documented 
causes of on-ART mortality (N=6) were one each of tuberculosis; cryptococcal 
meningitis; pneumonia and septicaemia; and unknown (3).   
 
Among 44 patients who did not meet TB case definitions based on investigations at 
enrolment but were not seen at the follow-up visit, 15 were known to have died 
(figure 1). 
  
 
DISCUSSION 
One-third of our patients referred to start ART had undiagnosed tuberculosis, a major 
burden of morbidity with life-threatening potential;10,11 highlighting the need to 
investigate all of these patients, most of whom were highly symptomatic, for 
tuberculosis. Our prevalence is similar to recent data from Western Cape (32%),12 
but higher than generally reported among ART-eligible adults in Africa (3%-
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19%).10,11,16,18-20  This reflects systematic screening of  our patients using multiple 
modalities, and a broad case definition allowing diagnosis based on radiological and 
clinical features highlighting the ‘real life’ burden, and recognising that sputum culture 
misses some cases of disseminated tuberculosis.21  Our 18% prevalence of culture-
confirmed pulmonary tuberculosis accords with studies from Cambodia (17%),22  
KwaZulu-Natal (19%),16 and Western Cape (17%).15   
 
We found demographic and clinical data unhelpful in identifying subgroups at higher 
risk of undiagnosed tuberculosis. Individuals with advanced HIV disease often reach 
HIV care due to symptoms of tuberculosis, underscoring the need for systematic 
case finding. Screening for this group requires high sensitivity to avoid missing 
cases, but in a resource-constrained setting, this must be balanced against the high 
costs resulting from a test combination with poor specificity. We found sputum 
microscopy had very poor sensitivity, consistent with other studies,16,19,23-25 yet this 
remains a key component of National Tuberculosis control programmes in resource 
limited settings. The WHO symptom screen17,26 had high sensitivity (96%) in our 
study population. It aims primarily to rule out tuberculosis among apparently healthy 
individuals prior to starting isoniazid preventive therapy, requiring a high sensitivity 
and negative predictive value; however this is at the cost of low specificity.  If all 
individuals identified as tuberculosis suspects, based on a symptom combination with 
relatively low specificity, are investigated with new rapid molecular diagnostics, such 
as Xpert MTB/RIF27 at US$17 per cartridge,28 the cost to health services may be 
substantial, and the cost-effectiveness of a range of algorithms for different settings 
needs to be investigated. 90% of our culture-proven tuberculosis cases were smear-
negative, and Xpert MTB/RIF has reported sensitivities from 43%-73% for smear-
negative culture-positive tuberculosis from a single sputum sample.15, 27 An algorithm 
requiring Xpert-negative tuberculosis suspects to undergo further evaluation using 
sputum culture, trial of antibiotic and chest radiograph has potential to delay 
tuberculosis treatment.  
 
Chest radiography improved sensitivity of our symptom screening complex 
substantially, consistent with our earlier data from South African gold miners with less 
advanced HIV disease.23  Use of chest radiography to augment the WHO symptom 
screen in high tuberculosis prevalence settings is supported by a recent meta-
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analysis26 and WHO guidance,17  and in our study population increased sensitivity 
and negative predictive value to 100%. Our data show that chest radiography 
facilitates prompt tuberculosis treatment initiation. Although implementation of chest 
radiography can be challenging,29,30 we suggest it should be done where possible. In 
high prevalence settings systematic sputum culture for all patients prior to ART has 
also been suggested, but presents the same challenges of access.12,16 In our study, 
most culture-positive patients started tuberculosis treatment based on clinical and 
radiological features prior to availability of culture results; even with liquid culture, the 
median time to tuberculosis treatment start based on a positive culture was 37 days. 
Chest radiography provides a basis for rapid initiation of tuberculosis treatment both 
to reduce individual risk of death and also reduce risk of onward transmission in both 
clinic and community, and procedures must be in place to ensure follow-up of 
tuberculosis suspects.30 The cost per chest radiograph has been estimated at only 
US$2.30  The reported sensitivity of Xpert MTB/RIF among smear-negative 
tuberculosis cases (most ART-eligible patients will be smear-negative) is lower than 
chest radiography in this study, but it has much higher specificity.27 Implementation of 
Xpert MTB/RIF should similarly reduce time to tuberculosis treatment start, but cost is 
likely to limit its wide use at peripheral health facilities, and effective low-cost point-of-
care diagnostic tools remain a pressing need.  
   
A low haemoglobin level is an independent predictor for mortality amongst patients 
commencing antiretroviral therapy31-33 and may reflect undiagnosed tuberculosis. 
Adding anaemia to our symptom complex increased sensitivity, and supports the 
clinical practice of investigating all anaemic patients for tuberculosis prior to initiation 
of ART. 
   
A major strength of our study was our longitudinal follow-up period, which is lacking 
from many screening studies,19 minimising the number of tuberculosis cases missed 
and ensuring a robust case definition for possible tuberculosis. One-third of 
participants without a review visit are known to have died, underscoring how ill 
individuals were at enrolment. Tuberculosis cannot be excluded as cause of death 
amongst all; hence we may have underestimated the true tuberculosis prevalence.  
The study setting in a large public sector clinic is relatively typical of antiretroviral roll 
out sites, although better resourced than many in sub-Saharan Africa. We had 
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access to routine radiographs, read by an experienced physician, and mycobacterial 
cultures, and good patient retention in the study. Our screening procedure was 
straightforward to operationalise and did not appear to delay initiation of ART; the 
typical time from first visit to ART initiation in this clinic was 60-90 days (personal 
communication, E Variaiva). 
 
In conclusion we found a very high prevalence of undiagnosed tuberculosis among 
patients presenting for ART to a public sector HIV clinic. These patients need routine 
systematic investigation for tuberculosis. Until accurate point-of-care diagnostic tests 
are available, our results suggest that chest radiography is a useful addition to 
routine screening which allows rapid initiation of tuberculosis treatment. Given the 
high mortality of patients awaiting investigation results,2,4,34 presumptive tuberculosis 
treatment for high-risk individuals also needs to be evaluated.35  
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FIGURE LEGEND 
Figure 1 Study inclusions, exclusions, case definitions and basis for diagnosis 
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Figure 1: Study inclusions, exclusions, case definitions and basis for diagnosis 
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Table 1: Performance of symptoms, signs, investigations and WHO stage as markers for 
undiagnosed prevalent tuberculosis*   
  
Marker Prevalence of marker 
(N=300)† 
% (n) 
Sensitivity 
(N=64) 
% (n) 
Specificity 
(N=236) 
% (n) 
PPV 
% 
NPV 
% 
SYMPTOMS      
Reported weight loss  90.0 (269/299) 90.5 (57/63) 10.2 (24) 21.2 80.0 
Any tiredness 69.3 (208) 81.3 (52) 33.9 (80) 25.0 87.0 
Tiredness > 2 weeks 47.0 (141) 70.3 (45) 59.3 (140) 31.9 88.1 
Any cough 44.0 (132) 68.8 (44) 62.7 (148) 33.3 88.1 
Cough > 2 weeks 24.3 (73) 43.8 (28) 80.9 (191) 38.4 84.1 
Cough > 3 weeks 22.3 (67) 42.2 (27) 83.1 (196) 40.3 84.1 
Any loss of appetite 50.0 (150) 62.5 (40) 53.4 (126) 26.7 84.0 
Loss of appetite > 2 weeks 32.0 (96) 51.6 (33) 73.3 (173) 34.4 84.8 
Any night sweats 40.7 (122) 59.4 (38) 64.4 (152) 31.2 85.4 
Night sweats > 2 weeks 28.7 (86) 45.3 (29) 75.9 (179) 33.7 83.6 
Any chest pain 46.3 (139) 53.1 (34) 55.5 (131) 24.5 81.4 
Chest pain > 2 weeks 27.3 (82) 37.5 (24) 75.4 (178) 29.3 81.7 
Any fever  27.0 (81) 35.9 (23) 75.4 (178) 28.4 81.3 
Fever > 2 weeks 12.7 (38) 25.0 (16) 90.7 (214) 42.1 81.7 
Any haemoptysis 7.7 (23) 9.4 (6) 92.8 (219) 26.1 79.1 
Any symptom‡ 96.3 (288/299) 96.8 (61/63) 3.8 (9) 21.2 81.8 
      
SIGNS:      
Body Mass Index  <18.5 kg/m
2
 26.5 (79/298) 37.5 (24) 76.5 (179/234) 30.4 81.7 
Temperature >37.4 ˚C  0.7 (2) 3.1 (2) 100 (236) 100 74.6 
      
INVESTIGATIONS:      
Haemoglobin <8 g/dl 4.0 (12/297) 6.3 (4) 96.6(225/233) 33.3 79.0 
Haemoglobin <10 g/dl 23.6 (70/297) 37.5 (24) 80.3(187/233) 34.3 82.4 
Total lymphocyte count (10^9/l) <1  22.4 (66/295) 28.1 (18) 79.2(183/231) 27.3 79.9 
CD4 cell count <100 cells/mm
3
 37.2 (111/298) 34.9 (22/63) 62.1(146/235) 19.8 78.1 
      
≥1 Sputum AFB Positive  2.3 (7/300) 10.9 (7) 100 (236) 100 80.6 
      
Abnormal CXR 58.9 (175/297) 85.5 (53/62) 48.1(113/235) 30.3 92.6 
CXR compatible with active TB 45.1 (134/297) 77.4 (48/62) 63.4(149/235) 35.8 91.4 
      
Clinical classification      
WHO clinical stage 3 or 4  53.8 (136/253) 55.6 (30/54) 46.7 (93/199) 22.1 79.5 
 
* Tuberculosis case defined as patients diagnosed within three months of recruitment who were culture-positive for 
tuberculosis; † denominator =300 unless otherwise indicated (all participants with probable [n=6] or possible [n=44]  
tuberculosis, and those without sputum culture results [n=11]  have been excluded); ‡ any of the following irrespective of 
duration: cough, sputum production, night sweats, self-reported weight loss, fever, haemoptysis, dyspnoea, chest pain, 
loss of appetite or fatigue; CXR = Chest radiograph; PPV= positive predictive value; NPV=negative predictive value; AFB 
= Acid-fast bacilli; HIV = human immunodeficiency virus; MTB = M. tuberculosis; WHO = World Health Organization 
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Table 2: Combinations of tuberculosis* screening criteria from this study and performance of WHO 
algorithm 17  in our study population (N=244)   
  
 Screening criteria: at least one of 
 
Present 
overall 
n=244 (%) 
Sensitivity % 
n=51 
(95% CI) 
Specificity % 
n=193 
(95% CI) 
PPV  % 
(95% CI) 
NPV % 
(95% CI) 
Symptoms only          
C>2w, A>2w, S>2w 133 (54.5) 74.5 (69.0, 80.0) 50.8 (44.5, 57.1) 28.6 (22.9, 34.2) 88.3 (84.3, 92.3) 
Addition of clinical features          
C>2w, A>2w, S>2w, WHO 3/4 190 (77.9) 90.2 (86.5, 93.9) 25.4 (19.9,30.9) 24.2 (18.8,  29.6) 90.7 (87.1, 94.4) 
C>2w, A>2w, S>2w, BMI<18.5  151 (61.9) 78.4 (73.3, 83.6) 42.5 (36.3, 48.7) 26.5 (21.0,32.0) 88.2 (84.1,92.2) 
C>2w, A>2w, S>2w, WHO 3/4, BMI<18.5 199 (81.6) 90.2 (86.5, 93.9) 20.7 (15.6, 25.8) 23.1 (17.8, 28.4) 88.9 (85.0, 92.8) 
Addition of basic laboratory tests          
C>2w, A>2w, S>2w, Hb <10 151 (61.9) 82.4 (77.6, 87.1) 43.5 (37.3, 49.7) 27.8 (22.2, 33.4) 90.3 (86.6,  94.0) 
C>2w, A>2w, S>2w, Hb<10, BMI<18.5  166  (68.0) 84.3 (79.8, 88.9) 36.3 (30.2, 42.3) 25.9 (20.4, 31.4) 89.7 (85.9, 93.6) 
C>2w, A>2w, S>2w,WHO 3/4, Hb<10, 
BMI<18.5  
204 (83.6) 90.2 (86.5, 93.9) 18.1 (13.3, 23.0) 22.6 (17.3, 27.8) 87.5 (83.4, 91.7) 
Addition of sputum microscopy          
C>2w, A>2w, S>2w, Sputum AFB-positive 135 (55.3) 78.4 (73.3, 83.6) 50.8 (44.5, 57.1) 29.6 (23.9, 35.4) 89.9 (86.1, 93.7) 
Addition of CXR          
C>2w, A>2w, S>2w,any CXR abnormality 195  (79.9) 96.1 (93.6, 98.5) 24.4 (19.0, 29.7) 25.1 (19.7,30.6) 95.9 (93.4, 98.4) 
C>2w, A>2w, S>2w,CXR compatible with 
active TB 
179 (73.4) 92.2 (88.8, 95.5) 31.6 (25.8, 37.4) 26.3 (20.7, 31.8) 93.9 (90.8, 96.9) 
Addition of CD4 count          
C>2w, A>2w, S>2w,CD4<100 171 (70.8) 82.4 (77.6, 87.1) 33.2 (27.3, 39.1) 24.6 (19.2, 30.0) 87.7 (83.6, 91.8) 
Addition of CXR and CD4           
C>2w, A>2w, S>2w,any CXR abnormality, 
CD4<100 
211 (86.5) 98.0 (96.3, 99.8) 16.6 (11.9, 21.3) 23.7 (18.4, 29.0) 97.0 (94.8, 99.1) 
C>2w, A>2w, S>2w,CXR compatible with 
active TB, CD4<100 
199 (81.6) 94.1 (91.2, 97.1) 21.8 (16.6, 26.9) 24.1 (18.8, 29.5) 93.3 (90.2,  96.5) 
WHO screening algorithm 
17
          
C, F, W, S 232 (95.1) 96.1 (93.6, 98.5) 5.2 (2.4, 8.0) 21.1 (16.0, 26.2) 83.3 (78.7, 88.0) 
C, F, W, S, any CXR abnormality 240 (98.3) 100 (100,100) 2.1 (0.3, 3.9) 21.3 (16.1, 26.4) 100 (100, 100) 
 
*Tuberculosis case defined as patients diagnosed within three months of recruitment who were culture-positive for tuberculosis. All 
participants with probable [n=6] or possible tuberculosis [n=44] and those without sputum culture results [n=11] have been excluded.  
Participants with missing data have also been excluded: WHO clinical stage [n=47], haemoglobin [n=3], chest radiograph [n=3], BMI 
[n=2], and reported weight loss [n=1]. 
A, appetite loss; C, cough; F, fever; S, night sweats; W, weight loss 
PPV= positive predictive value; NPV=negative predictive value; 2w=2 weeks; WHO = World Health Organization clinical stage; BMI=Body 
mass index (kg/m
2
); Hb=Haemoglobin g/dl; AFB = Acid-fast bacilli; CXR = Chest radiograph; CD4 = CD4 cell count (cells/mm
3
); 
TB=tuberculosis 
 
 
